Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Addeo

Showing results (151-160 of 224) with videos related to

Pageof 23
Sort By:
Journal of Clinical Medicine|March 25, 2022
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and TreatmentAbed Agbarya, Walid Shalata, Alfredo Addeo, et al.
The Oncologist|July 29, 2022
International Survey on Frailty Assessment in Patients with CancerGiuseppe Luigi Banna, Ornella Cantale, Maria Monica Haydock, et al.
JCO Oncology Practice|February 13, 2020
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline SummaryVittorio Fusco, Daniele Santini, Giuseppina Campisi, et al.
Current Oncology Reports|October 18, 2022
Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung CancerGiuseppe Luigi Banna, Alex Friedlaender, Marco Tagliamento, et al.
Cancer Biology & Therapy|February 3, 2005
Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune responseAnna Carbone, Ulrich Rodeck, Francesco Angelo Mauri, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2025
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)Alfredo Addeo, Daniel Dietrich, Nicolas Mach, et al.
Frontiers in Oncology|September 25, 2020
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer PatientsChristian Britschgi, Alfredo Addeo, Markus Rechsteiner, et al.
Cancer Treatment Reviews|January 3, 2026
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?Seng Wee Cheo, Molly S C Li, Derek De-Rui Huang, et al.
Cancer Treatment Reviews|February 20, 2025
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the targetGiannis Mountzios, Stephanie P L Saw, Lizza Hendriks, et al.
Translational Lung Cancer Research|September 12, 2022
Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysisDongliang Bian, Siming Jiang, Yicheng Xiong, et al.
Pageof 23

Showing results (151-160 of 224) with videos related to

Sort By:
Pageof 23
Journal of Clinical Medicine|March 25, 2022
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and TreatmentAbed Agbarya, Walid Shalata, Alfredo Addeo, et al.
The Oncologist|July 29, 2022
International Survey on Frailty Assessment in Patients with CancerGiuseppe Luigi Banna, Ornella Cantale, Maria Monica Haydock, et al.
JCO Oncology Practice|February 13, 2020
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline SummaryVittorio Fusco, Daniele Santini, Giuseppina Campisi, et al.
Current Oncology Reports|October 18, 2022
Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung CancerGiuseppe Luigi Banna, Alex Friedlaender, Marco Tagliamento, et al.
Cancer Biology & Therapy|February 3, 2005
Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune responseAnna Carbone, Ulrich Rodeck, Francesco Angelo Mauri, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2025
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)Alfredo Addeo, Daniel Dietrich, Nicolas Mach, et al.
Frontiers in Oncology|September 25, 2020
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer PatientsChristian Britschgi, Alfredo Addeo, Markus Rechsteiner, et al.
Cancer Treatment Reviews|January 3, 2026
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?Seng Wee Cheo, Molly S C Li, Derek De-Rui Huang, et al.
Cancer Treatment Reviews|February 20, 2025
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the targetGiannis Mountzios, Stephanie P L Saw, Lizza Hendriks, et al.
Translational Lung Cancer Research|September 12, 2022
Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysisDongliang Bian, Siming Jiang, Yicheng Xiong, et al.
Pageof 23